UNSPSC 51312702: Histapyrrodine

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0FYM61NG4D. European Medicines Agency schedules Histapyrrodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08044MIG. Histapyrrodine generally arises in the molecular formula C19H24N2.

UNSPSC 51312702 Histapyrrodine, a Commodity code, shows minimal alignment between its nominal scope and the recent state and local opportunities tagged under it. The three most recent solicitations—from Seminole County, Florida; Texas Health and Human Services Commission; and Minnesota Multistate Cooperative Purchasing Alliance—involve naloxone procurement, therapeutic pharmacy initiative direct-to-manufacturer programs, and generic multi-source pharmaceutical and OTC product supply contracts. None of these opportunities concern histapyrrodine specifically, a pharmaceutical intermediate compound. The code appears to capture state and local purchases of pharmaceuticals, naloxone products, and pharmacy benefit management services more broadly, though the tagging is imprecise and does not reliably distinguish histapyrrodine from other pharmaceutical commodities or drug-based products.

The issuing bodies include a county government (Seminole County), a state health and human services agency (Texas HHS), and a multi-state cooperative purchasing consortium (Minnesota MMCAP, representing state and local government members across multiple states including Oregon). Recent activity concentrates in Florida, Texas, and the Upper Midwest, with secondary reach into the Pacific Northwest through MMCAP's multi-state membership. Representative recent solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023—note the conflicting dates in the source) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries; Texas HHS's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment capabilities; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers. The code shows activity but lacks reliable recent opportunities specific to histapyrrodine procurement.